Alpha 1-antitrypsin deficiency other diagnostic studies: Difference between revisions
Mazia Fatima (talk | contribs) No edit summary |
Mazia Fatima (talk | contribs) |
||
| Line 9: | Line 9: | ||
==Other Diagnostic Studies== | ==Other Diagnostic Studies== | ||
===Phenotyping=== | ===Phenotyping=== | ||
Patients with low or borderline serum levels are tested with phenotyping (serum levels < 100 mg/dL) by isoelectric focusing (IEF) is the most commonly used method to definitively detect the alpha1-antitrypsin phenotype that indicates a risk for AATD. | Patients with low or borderline serum levels are tested with phenotyping (serum levels < 100 mg/dL) by isoelectric focusing (IEF) is the most commonly used method to definitively detect the alpha1-antitrypsin phenotype that indicates a risk for AATD. <ref name="pmid18433707">{{cite journal |vauthors=Ljujic M, Topic A, Divac A, Nikolic A, Petrovic-Stanojevic N, Surlan M, Mitic-Milikic M, Radojkovic D |title=Isoelectric focusing phenotyping and denaturing gradient gel electrophoresis genotyping: a comparison of two methods in detection of alpha-1-antitrypsin variants |journal=Transl Res |volume=151 |issue=5 |pages=255–9 |year=2008 |pmid=18433707 |doi=10.1016/j.trsl.2008.02.002 |url=}}</ref><ref name="pmid28178162">{{cite journal |vauthors=Al-Jameil N, Hassan AA, Buhairan A, Hassanato R, Isac SR, Al-Otaiby M, Al-Maarik B, Al-Ajeyan I |title=Genotyping diagnosis of alpha-1 antitrypsin deficiency in Saudi adults with liver cirrhosis |journal=Medicine (Baltimore) |volume=96 |issue=6 |pages=e6071 |year=2017 |pmid=28178162 |pmc=5313019 |doi=10.1097/MD.0000000000006071 |url=}}</ref> | ||
Phenotyping is required to confirm AATD. Do not initiate alpha1-antitrypsin replacement therapy without testing. | Phenotyping is required to confirm AATD. Do not initiate alpha1-antitrypsin replacement therapy without testing. | ||
PiZZ phenotype is responsible for nearly all cases of AATD emphysema and liver disease. | PiZZ phenotype is responsible for nearly all cases of AATD emphysema and liver disease. | ||
Revision as of 01:37, 16 December 2017
|
Alpha 1-antitrypsin deficiency Microchapters |
|
Differentiating Alpha 1-antitrypsin deficiency from other Diseases |
|---|
|
Diagnosis |
|
Treatment |
|
Case Studies |
|
Alpha 1-antitrypsin deficiency other diagnostic studies On the Web |
|
American Roentgen Ray Society Images of Alpha 1-antitrypsin deficiency other diagnostic studies |
|
FDA on Alpha 1-antitrypsin deficiency other diagnostic studies |
|
CDC on Alpha 1-antitrypsin deficiency other diagnostic studies |
|
Alpha 1-antitrypsin deficiency other diagnostic studies in the news |
|
Blogs on Alpha 1-antitrypsin deficiency other diagnostic studies |
|
Directions to Hospitals Treating Alpha 1-antitrypsin deficiency |
|
Risk calculators and risk factors for Alpha 1-antitrypsin deficiency other diagnostic studies |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief:
Please help WikiDoc by adding content here. It's easy! Click here to learn about editing.
Overview
Patients with low or borderline serum levels are tested with phenotyping (serum levels < 100 mg/dL) by isoelectric focusing (IEF) is the most commonly used method to definitively detect the alpha1-antitrypsin phenotype that indicates a risk for AATD. Genotyping uses DNA extracted from circulating mononuclear blood cells that utilizes DNA amplification techniques with melt-curve analysis.
Other Diagnostic Studies
Phenotyping
Patients with low or borderline serum levels are tested with phenotyping (serum levels < 100 mg/dL) by isoelectric focusing (IEF) is the most commonly used method to definitively detect the alpha1-antitrypsin phenotype that indicates a risk for AATD. [1][2] Phenotyping is required to confirm AATD. Do not initiate alpha1-antitrypsin replacement therapy without testing. PiZZ phenotype is responsible for nearly all cases of AATD emphysema and liver disease. PiSZ and PiZ/Null are other phenotypes associated with alpha1-antitrypsin emphysema and liver disease. PiNull/Null is not associated with liver disease but is associated with alpha1-antitrypsin deficiency emphysema.
Genotyping
Genotyping uses DNA extracted from circulating mononuclear blood cells that utilizes DNA amplification techniques with melt-curve analysis.
References
- ↑ Ljujic M, Topic A, Divac A, Nikolic A, Petrovic-Stanojevic N, Surlan M, Mitic-Milikic M, Radojkovic D (2008). "Isoelectric focusing phenotyping and denaturing gradient gel electrophoresis genotyping: a comparison of two methods in detection of alpha-1-antitrypsin variants". Transl Res. 151 (5): 255–9. doi:10.1016/j.trsl.2008.02.002. PMID 18433707.
- ↑ Al-Jameil N, Hassan AA, Buhairan A, Hassanato R, Isac SR, Al-Otaiby M, Al-Maarik B, Al-Ajeyan I (2017). "Genotyping diagnosis of alpha-1 antitrypsin deficiency in Saudi adults with liver cirrhosis". Medicine (Baltimore). 96 (6): e6071. doi:10.1097/MD.0000000000006071. PMC 5313019. PMID 28178162.